Chiasma to Present at Upcoming Investor Conferences

NEWTON, Mass., Feb. 25, 2016 -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide) capsules, a new investigational oral drug for the potential maintenance therapy of adult patients with the orphan disease acromegaly, today announced that President and Chief Executive Officer Mark Leuchtenberger will provide a corporate overview during the following two upcoming investor conference presentations:

• Cowen and Company 36th Annual Health Care Conference in Boston on Monday, March 7, 2016 at 2:40 p.m. ET.
• Barclays Global Healthcare Conference 2016 in Miami on Wednesday, March 16, 2016 at 1:35 p.m. ET.

A live and archived audio webcast of each presentation will be available under the News & Investors section of Chiasma’s website at www.ChiasmaPharma.com.

About Chiasma

Chiasma is a late-stage biopharmaceutical company focused on improving the lives of patients suffering from orphan diseases by developing and commercializing novel oral forms of therapies that are available today only by injection.  The company’s lead product candidate is Mycapssa™ (octreotide) capsules, a new investigational drug for the orphan condition acromegaly, developed with Chiasma’s Transient Permeability Enhancer (TPE^®) technology to facilitate gastrointestinal absorption of unmodified drug into the bloodstream safely.  Mycapssa™ is a proposed tradename, and this new investigational drug has not been approved for use in any jurisdiction.  Using TPE^® technology, Chiasma is evaluating additional proteins, peptides and small molecule drugs that are currently only available by injection, but could potentially be converted to oral delivery.  TPE^® technology is potentially well suited for drugs with chronic indications, where frequent dosing is required and the need for an oral alternative is greatest.  Chiasma is a Delaware corporation with a wholly owned Israeli subsidiary. Mycapssa™ and TPE^® are trademarks of Chiasma.

Additional information can be found at www.ChiasmaPharma.com. 

Online Resources

Readers should note that Chiasma communicates with investors and the public using its website (www.ChiasmaPharma.com) and its investor relations website (http://ir.chiasmapharma.com), including but not limited to company disclosures; investor presentations and FAQs; Securities and Exchange Commission filings; press releases; public conference calls and webcasts. The information that the company posts on these websites could be deemed to be material information. As a result, Chiasma encourages investors, the media, and others interested to review the information that is posted there on a regular basis. The contents of the company’s website shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Contacts:
Media:
Cammy Duong                                                                                   
MacDougall Biomedical Communications                                                    
(781) 591-3443                                                                       
[email protected]

Investors:
Jason Fredette
Chiasma, Inc.
(617) 928-5306
[email protected]